RestorGenex Corp  

(Public, OTCMKTS:RESX)   Watch this stock  
Find more results for B. Blech
+0.09 (2.92%)
Delayed:   10:35AM EST
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 3.05 - 3.21
52 week 2.37 - 10.20
Open 3.10
Vol / Avg. 9,456.00/6,734.00
Mkt cap 59.03M
P/E     -
Div/yield     -
EPS -1.07
Shares 18.62M
Beta 0.60
Inst. own 0%
Feb 10, 2015
RestorGenex Corp at Biotechnology Industry Organization CEO & Investor Conference - 2:30PM EST - Add to calendar
Jan 13, 2015
RestorGenex Corp at EBD Biotech Showcase
Nov 12, 2014
Q3 2014 RestorGenex Corp Earnings Release

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -3429.54%
Operating margin - -18023.34%
EBITD margin - -10096.50%
Return on average assets -26.33% -23.65%
Return on average equity -31.41% -
CDP Score - -


2150 E Lake Cook Rd Ste 750
BUFFALO GROVE, IL 60089-8227
United States - Map
+1-805-2291829 (Phone)
+1-213-9956337 (Fax)

Website links


RestorGenex Corp, formerly Stratus Media Group, Inc., is a biopharmaceutical company initially focused on developing products for dermatology, ophthalmology and women�s health. The Company�s proposed product portfolio includes a cosmeceutical product line. The Company is engaged in product development for both the cosmeceutical market, as well as the prescription dermatology market. The Company�s opthalmology business is based upon developing a non-steroidal, synthetic, small molecule drug library through computational design, and synthetic and medicinal chemistry, resulting in a family of agents, called Palomids. The Company also is engaged in the prescription women�s health business. Effective June 30, 2013, the Company suspended development of its ProElite, Inc. (ProElite) mixed martial arts (MMA). On March 28, 2014, the Company acquired Paloma Pharmaceuticals, Inc and VasculoMedics, Inc.

Officers and directors

Sol J. Barer Chairman of the Board
Age: 67
Stephen M. Simes Chief Executive Officer, Director
Age: 62
Isaac Blech Vice Chairman of the Board
Age: 64
Phillip B. Donenberg Chief Financial Officer, Secretary
Age: 53
Yael Schwartz Ph.D. President of Canterbury Laboratories LLC, and Hygeia Therapeutics, Inc., Director
Age: 65
Mark Weinberg M.D. Senior Vice President - Clinical Development
David Sherris M.D., Ph.D. Chief Scientific Officer, President - Paloma/VasculoMedics Divisions, Director
Age: 61
Craig Abolin Vice President - Research and Development of Canterbury Laboratories LLC, and Hygeia Therapeutics, Inc.
Age: 66
Rex Bright Director
Age: 74
Nelson K. Stacks Director
Age: 43